Acylhydrazone derivatives and the use thereof in the inhibition, regulation and/or modulation of kinase signal transduction

US7405239B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Rolf Gericke · Seeheim-Jugenheim, DE
• Norbert Beier · Reinheim, DE
• Oliver Poeschke · Wiesbaden, DE
• Lars Burgdorf · Frankfurt am Main, DE
• Helga Drosdat · Heppenheim, DE
• Florian Lang · Gilching, DE

Key dates

• Filing date: Sep 16, 2004
• Grant date: Jul 29, 2008
• Expiry date: Oct 6, 2024

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to acylhydrazone derivatives of formula (I), which are SGK inhibitors and can be used for the treatment of diseases and afflictions associated with SGK, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systematic and pulmonary hypertension, cardiovascular diseases and kidney diseases and in general for all types of fibroses and inflammatory processes. In said formula: R1 and R5 independently of one another represent H, OH, OA, OAc or methyl; R2, R3, R4, R6, R7, R8, R9 and R10 independently of one another represent H, OH, OA, OAc, OCF3, Hal, NO2, CF3, A, CN, OSO2CH3, SO2CH3, NH2, or COOH; R11 represents H or CH3; A represents an alkyl comprising 1, 2, 3, or 4 C atoms; X represents CH2, CH2CH2, OCH2 or —CH(OH)— and Hal represents F, Cl, Br or I.